Search

Search

Popular peptides
↑ ↓ to move ↵ to openBrowse all peptides

Research peptides vs compounded vs brand-name

Three vials labeled 10 mg of retatrutide, tested by an Australian drug-checking service, held 5.1 mg, 16.5 mg and 19.0 mg.1 A brand-name drug, a pharmacy’s compounded version and a “research use only” vial can hold the same peptide, but they come with very different checks. Here’s what each one guarantees, and what lab tests found inside vials sold online.

Updated · 58 sources

The short version

  1. “Research use only” means nobody checked it for people. FDA says the label doesn’t make a peptide legal to sell when it’s sold for people to use.23 What the label means
  2. Compounded isn’t FDA-approved either, but pharmacies are licensed, and outsourcing facilities follow federal manufacturing rules and get FDA inspections.45 What each vial guarantees
  3. About 4 in 10 “research” peptide samples failed a basic lab standard in the largest study so far, mostly because the vial held the wrong amount.6 What lab tests found
  4. A 99% purity certificate doesn’t tell you the dose, whether the vial is sterile, or whether the vial tested was yours.78 What a certificate proves
  5. Brand-name drugs can be faked too, so FDA says to get a prescription and fill it at a state-licensed pharmacy.39 Lowering the risk

What does “research use only” mean?

It’s a label saying a product is for lab research, not for people. FDA says sellers who label peptides “for research purposes” or “not for human consumption” but sell them to the public with dosing instructions are illegally selling unapproved drugs.

  • The label doesn’t change the rules. In warning letters from 2024 to 2026, FDA said “research chemicals only,” “research use only” and “not for human consumption” labels don’t matter when a seller’s website shows the product is meant for people.2101112

“Despite statements on your product labeling marketing your products as “research chemicals only” and “not for human consumption,” evidence obtained from your website establishes that your products are intended to be drugs for human use.”

U.S. Food and Drug AdministrationWarning letter to an online seller, February 20242
  • Selling the mixing water counts. In August 2026, FDA told one seller that offering bacteriostatic water to dissolve its products provided the means to prepare an injectable drug for people.12
  • No prescription, and often no instructions. Research-labeled GLP-1 vials are sold without a prescription and often without the supplies or know-how to mix and inject them. In a 2026 study, 20 adults given vials and supplies, with only online information to go on, got 15 of 34 preparation and injection steps right on average.1314 How to inject
  • Some can’t be sold legally at all. Retatrutide isn’t approved for any use and can’t legally be compounded, FDA says, so any retatrutide sold to the public is an unapproved drug.3 Where retatrutide stands

What does each kind of vial guarantee?

A brand-name drug was reviewed by FDA before it went on sale, and every batch is tested. A compounded drug isn’t FDA-approved, but the pharmacy is licensed and regulated. Nothing requires any checks on a “research use only” vial.

What each kind of vial guaranteesWhat the law requires of each, and what FDA checks
Brand-nameFDA-approvedOutsourcing503B facilityPharmacy503AResearchuse only
FDA reviewed it for safety and effectiveness before sale3415YesNoNoNo
FDA reviewed how it’s made before sale1516YesNoNoNo
Federal manufacturing rules apply, including testing every batch5171819YesYesNoNo
FDA inspects the maker on a schedule52021YesYesPartlyNo
Ingredient checked against a certificate of analysis222324YesYesYesNo
FDA-approved label with doses and warnings152324YesNoNoNo
Maker must report serious side effects to FDA32425YesYesNoNo
Sold only with a prescription232426YesPartlyYesNo

“Partly”: state boards, not FDA, oversee pharmacies day to day, and outsourcing facilities can supply a clinic without a patient’s name. “No” means nothing requires it, not that it never happens: some sellers test their products, but nobody checks that they do.

  • Brand-name. Before approval, FDA decides whether the drug is safe and effective, whether its label is right, and whether the way it’s made preserves its identity, strength, quality and purity. After approval, the maker must report serious, unexpected side effects within 15 days.1525
  • Compounded. Made by a pharmacy for a patient’s prescription, under section 503A of federal drug law, or by an outsourcing facility under section 503B. FDA reviews neither before it reaches patients.42324 How pharmacies are checked
  • Research use only. Any testing is up to the seller, and a test of one sample may not reflect your vial. In the largest set of lab reports studied, under 4% included a test for bacterial toxins.6 What a certificate shows
  • Brand-name drugs get recalled too. Of the 17 semaglutide and tirzepatide recalls FDA reported from January 2023 to October 2026, 2 were for brand-name Wegovy: possible heat exposure in shipping, and a hair found in a syringe.27

How are compounding pharmacies checked?

Ordinary compounding pharmacies are overseen mainly by state pharmacy boards and don’t have to follow federal manufacturing rules. Outsourcing facilities register with FDA, follow those rules, and are inspected by FDA on a schedule set by risk.

“Compounded drugs are not FDA-approved. This means that FDA does not review these drugs to evaluate their safety, effectiveness, or quality before they reach patients.”

U.S. Food and Drug AdministrationOn compounded drugs4
  • Pharmacies (503A). They make a drug for a named patient with a valid prescription. They’re exempt from FDA approval and from federal manufacturing rules, and don’t have to report side effects to FDA. State boards of pharmacy oversee them day to day, and FDA also does some inspections, including when there’s a problem.3523
  • Outsourcing facilities (503B). They make sterile drugs and can supply a clinic without a patient’s name. They must follow federal manufacturing rules, report serious side effects and print “This is a compounded drug” on the label. Congress created them in 2013, after contaminated injections from one pharmacy caused a deadly outbreak.452124
FDA’s 98 registered outsourcing facilities
  • Inspected, and handed a Form 483 listing problems at the last inspection
  • Inspected, with no Form 483
  • Not inspected yet

Each square is one facility, as of September 30, 2026. A Form 483 lists conditions inspectors found objectionable; FDA says it isn’t a final finding that the law was broken.28

  • Rules on ingredients. A pharmacy’s ingredient must meet a USP standard, be part of an approved drug or be on FDA’s list of allowed bulk ingredients, and come from an FDA-registered maker with a certificate of analysis.2324
  • BPC-157: no final decision yet. FDA added it to its list of compounding ingredients that may pose significant safety risks on September 29, 2023. In July 2026, FDA proposed keeping it out of compounding, citing poor characterization and missing safety data. FDA’s outside advisers then voted 8–6 to recommend allowing it, ABC News reported; the vote isn’t binding, and we found no final decision as of October 2026.82930 BPC-157 profile
  • Copies of Wegovy and Zepbound are restricted. With the shortages over, pharmacies may not regularly make copies of Wegovy or Zepbound, and FDA counts semaglutide with added vitamin B12 at nearly the same strength as still a copy. In April 2026, FDA also proposed barring outsourcing facilities from making semaglutide, tirzepatide or liraglutide from bulk powder.3132
  • Retatrutide can’t be compounded. FDA has warned telehealth companies, distributors that sold it to compounders, and outsourcing facilities that repackaged it.3
  • The standards pharmacies follow. Instead of federal manufacturing rules, pharmacies follow state rules and USP’s standards for sterile compounding, last revised in 2023. USP sells the standards by subscription, so we couldn’t check what testing they require.33

What did lab tests of online peptides find?

In the largest look so far, 42% of samples of 14 “research” peptides failed a basic lab standard, mostly because the vial held the wrong amount. Smaller studies found vials holding half, or nearly double, the dose on the label.

  • The biggest look so far. A 2026 preprint, not yet peer reviewed, reanalyzed 6,487 lab reports on 14 peptides from 203 companies, sent to one public testing service by buyers and sellers between December 2024 and April 2026.6
Most failures were the wrong amount, not impuritiesWhy samples of 14 “research” peptides failed a basic lab standard, as a share of all 6,441 samples
  1. Wrong amount, but pure32.8%
  2. Wrong amount and impure3.3%
  3. Impure, but the right amount3.0%
  4. Not the peptide on the label2.4%

The standard, based on pharmacy compounding rules: 90–110% of the labeled amount and at least 98% purity. 58.4% of samples passed. From a 2026 preprint that hasn’t been peer reviewed, of lab reports sent in by buyers and sellers.6

  • The typical vial looked fine. The median sample held 101.8% of its labeled amount at 99.8% purity. The trouble was the spread: a quarter held less than 95% of the label, and a quarter more than 109%.6
  • Under a stricter standard, most failed. Held to 95–105% of the label and 99.5% purity, which the authors modeled on factory-made drugs, 71% failed.6
  • What it can’t tell you. The reports had no results for sterility, solvents, particles or stability, and buyers and sellers chose what to send in, so the authors call the failure rates a lower bound.6
What was really in the vialAmount of drug measured in each vial, as a share of what its label claimed
  1. What the label claims100%
  2. Brand-name Ozempic penTested alongside for comparison, US105%
  3. Semaglutide bought online, lowest of 3Sold without a prescription, US129%
  4. Semaglutide bought online, highest of 3Sold without a prescription, US139%
  5. “Retatrutide,” vial 1Labeled 10 mg, Australia51%
  6. “Retatrutide,” vial 2Labeled 10 mg, Australia165%
  7. “Retatrutide,” vial 3Labeled 10 mg, Australia190%

Two small studies: 3 semaglutide vials ordered from online sellers in the US, and 3 retatrutide vials given to a drug-checking service in Australia. Semaglutide made up only 7–14% of each US vial’s powder.134

  • Half the semaglutide orders never came. In a 2024 study, US researchers ordered from 6 online sellers. Only 3 vials arrived; the other 3 sellers were scams that asked for extra “customs” payments. All 3 vials held semaglutide, 29% to 39% more than labeled, but it made up only 7% to 14% of the powder, not the 99% advertised. One had raised bacterial toxin levels.3435
  • “Retatrutide” in Australia. Three vials labeled 10 mg, given to a drug-checking service, held 5.1 mg, 16.5 mg and 19.0 mg. Another product sold as retatrutide held semaglutide and no retatrutide when Australia’s drug regulator tested it, JAMA reported.136
  • Liver injuries in Victoria. In June 2026, Victoria’s health department reported 6 cases of acute liver injury since January in people using products labeled retatrutide, possibly from a contaminant.37 Warning signs to know
  • Copies of brand-name GLP-1s. Studies by the brand-name makers, which compete with these products, found new, unidentified impurities in copycat semaglutide and liraglutide, oral copies with far less semaglutide than labeled, and a new impurity that forms when tirzepatide is mixed with some forms of vitamin B12.383940

Which peptides failed most often?

In a 2026 analysis of 6,441 lab reports, TB-500 and CJC-1295 failed a basic standard most often, about 78% and 71% of the time, and about 1 in 10 of their samples weren’t the labeled peptide at all. Retatrutide failed least, 32% of the time.

How often each peptide failedShare of samples that held the wrong amount, were under 98% pure, or weren’t the peptide on the label
  1. All 14 peptides6,441 samples42%
  2. TB-500About 40 samples, too few to be sure78%
  3. CJC-1295About 240 samples71%
  4. BPC-157About 490 samples57%
  5. TesamorelinAbout 310 samples50%
  6. GHK-CuAbout 380 samples48%
  7. CagrilintideAbout 90 samples45%
  8. PT-141About 90 samples44%
  9. IpamorelinAbout 260 samples44%
  10. TirzepatideAbout 1,700 samples42%
  11. SermorelinAbout 25 samples, too few to be sure41%
  12. SemaglutideAbout 300 samples41%
  13. SurvodutideAbout 25 samples, too few to be sure36%
  14. Thymosin beta-4About 30 samples, too few to be sure36%
  15. RetatrutideAbout 2,400 samples32%

From a 2026 preprint that hasn’t been peer reviewed. Most single-peptide rates were read off its charts, so treat them as approximate, and rates from small samples could move a lot with more testing.6

  • Sometimes it’s the wrong peptide. Samples of TB-500 (10.0%), CJC-1295 (9.1%), tesamorelin (3.6%) and BPC-157 (3.5%) were the most likely not to be the peptide on the label.6
  • Under the stricter standard, only 7.5% of TB-500 samples, 10.7% of CJC-1295 and 13.8% of tirzepatide passed. Tirzepatide was usually pure but held the wrong amount.6
  • Purity varied too. Median purity was lowest for TB-500, at 97.3%, and CJC-1295, at 98.5%.6
  • TB-500 isn’t always TB-500. A French anti-doping lab found products sold online as TB500 and TB1000 weren’t consistently what they claimed.41 TB-500 profile

What does a certificate of analysis prove?

Only what one lab found in one sample. Most peptide certificates report just HPLC purity, which isn’t the dose and says nothing about germs or bacterial toxins. A vial can be 99% pure and still hold the wrong amount.

  • Purity isn’t the amount. HPLC purity is the peptide’s share of what the instrument detects. Water, salts and anything else it doesn’t see are left out, so it can’t tell you how many milligrams are in the vial.67
  • Pure powder isn’t all peptide. Peptides made the standard way usually come as salts. In a worked example by USP scientists, a powder about 99% pure held 0.93 mg of peptide per milligram once salt and water were counted.742
  • A real example. One maker listed a lot of synthetic glucagon at 983.7 mg per gram; China’s national metrology institute measured 896.4.43
  • Purity didn’t predict the rest. In the 2026 preprint, a third of all samples passed on purity but held the wrong amount, and purity didn’t predict bacterial toxins.6
  • What FDA found for BPC-157. Most certificates show only a purity number, with no limits for impurities, and one FDA reviewed had no results for impurities, clumped peptide, germs or bacterial toxins. For anything injected, FDA treats sterility, bacterial toxins and particles as critical checks.8

“While CGMP requires testing, testing alone is not adequate to ensure quality.”

U.S. Food and Drug AdministrationOn the rules for making drugs44
  • Only a sample is tested. FDA’s example: a maker may test 100 tablets from a batch of 2 million.44
  • Your vial isn’t the one tested. FDA cited one ingredient distributor for relying on samples sent straight from the factory to the lab, instead of testing what arrived after shipping. Light can change a product after testing, too: two compounded vials left in light lost 5% and 14% of their strength in one study.3845
  • Even a full certificate isn’t a guarantee. The preprint’s authors write that a third-party certificate doesn’t guarantee the safety of a drug meant for injection.6

Why do sterility and bacterial toxins matter?

Anything injected has to be free of germs and low in bacterial toxins called endotoxins. Brand-name makers and outsourcing facilities must test every sterile batch for both. Few “research” vials are tested for either.

  • How much toxin is too much. Injected drugs are held to 5 endotoxin units per kilogram of body weight per hour, counting everything injected: 350 units an hour for a 70 kg (154 lb) adult.464748
  • Research vials are rarely tested. Of the 6,487 lab reports in the 2026 preprint, 243 included a toxin test, and 36 of those (15%) found measurable endotoxin. None reported sterility.6 Signs of a bad batch
  • A clean test isn’t proof. Sterility tests use only a few units. Even if 1 unit in 10 in a batch is contaminated, the standard test misses it about 1 time in 10.49
  • Most recalls involved compounding. Of the 17 semaglutide and tirzepatide recalls FDA reported from January 2023 to October 2026, 15 involved compounded drugs or a compounding ingredient, 9 of them because sterility couldn’t be assured. In one, a vial labeled tirzepatide held testosterone.27
  • When it goes badly wrong. In 2012, contaminated steroid injections from one compounding pharmacy caused 753 cases of fungal meningitis and other infections, and 64 deaths, in 20 states.450

Can a brand-name drug be fake?

Yes. FDA found counterfeit Ozempic in the U.S. drug supply in December 2023 and twice in 2025. FDA’s advice is to get a prescription from your doctor and fill it at a state-licensed pharmacy.

“Counterfeit drugs claim to be authentic, but could contain the wrong ingredients, contain too little, too much or no active ingredient at all or other harmful ingredients, and are illegal.”

U.S. Food and Drug AdministrationOn fake GLP-1 drugs3
  • December 2023: fake Ozempic pens. FDA seized thousands of fake Ozempic 1 mg pens, lot NAR0074. The needles were fake too, so their sterility couldn’t be confirmed.9
  • 2025: more fakes. Several hundred fake pens, lot PAR0362, in April, and dozens more, reported in December, that carried a real lot number, PAR1229. FDA asks pharmacies and patients to check what they’ve received.9
  • Fake “compounded” drugs, too. FDA knows of fake “compounded” semaglutide and tirzepatide whose labels name licensed pharmacies that didn’t make them.3
  • Most online pharmacies don’t follow the rules. About 35,000 are active at any time, and about 5% follow U.S. pharmacy laws, FDA said in 2020, citing the National Association of Boards of Pharmacy.51
  • Signs of a safe one. FDA says a safe online pharmacy always requires a prescription, has a U.S. address and phone number, has a licensed pharmacist to answer questions, and is licensed by a state board of pharmacy. Prices that seem too good to be true are a warning sign.26

What is FDA doing about research peptides?

Sending warning letters and stopping imports. FDA’s warning-letter search finds 21 letters that mention retatrutide since December 2024, and an import alert aims to keep suspect GLP-1 ingredients out of the country.

FDA’s warning letters about GLP-1 drugs have soaredFDA warning letters that mention each drug, by the year they were sent
  1. 20232 semaglutide1 tirzepatide
  2. 202410 semaglutide5 tirzepatide
  3. 202567 semaglutide43 tirzepatide
  4. 2026Through October 1670 semaglutide64 tirzepatide

Counted with FDA’s own warning-letter search. The letters went to online sellers, telehealth companies, pharmacies and ingredient suppliers. Only 2 letters mention BPC-157, from 2021 and 2023.52

  • 21 letters about retatrutide. They went out in December 2024 (4), September 2025 (6), December 2025 (1, to an ingredient distributor), January 2026 (1, to a compounding pharmacy), March 2026 (4) and August 2026 (5). JAMA counted the same total.3652 Why Lilly is suing FDA over retatrutide
  • 2025 in numbers. FDA’s drug compliance office sent 314 warning letters in 2025, including 72 about compounding, 58 of them to telehealth companies, and 37 to online pharmacies.53
  • At the border. A “green list” import alert, 66-80, helps stop GLP-1 ingredients with potential quality problems from entering the U.S.3
  • Hospitalizations reported. JAMA cites a Public Citizen count of at least 14 hospitalized users of retatrutide products, from FDA’s side-effect reports. Doctors have also published cases of severe nausea, and of a person with type 1 diabetes who came close to ketoacidosis, after using retatrutide bought online.365455

How can you lower the risk of a bad vial?

Use an FDA-approved drug with a prescription when there is one. If you’re prescribed a compounded drug, find out who makes it. No certificate turns a “research use only” vial into a checked medicine.

  • Start with approved drugs. FDA reviews approved medicines for safety, effectiveness and quality.56 What FDA approval means
  • Ask where a compounded drug is made. FDA lists every registered outsourcing facility, with the date of its last inspection and whether it got a Form 483. State boards license pharmacies.528
  • Read the label. An outsourcing facility’s label must say “This is a compounded drug” and give its name, address and phone number.24
  • Check the dose math. FDA has reports of people injecting 5 to 20 times their intended dose of compounded semaglutide, and says confusion between milliliters, milligrams and “units” may have contributed.57 Mixing calculator
  • Keep it cold, and don’t keep it long. FDA says not to use an injectable GLP-1 that arrives warm, and generally recommends throwing out a multi-dose vial 28 days after first use.3 FDA’s review of BPC-157 notes the powder keeps best frozen and dry, and that once mixed it’s reported stable for 2–3 weeks in a fridge.8 Vial care
  • Report problems. Tell your doctor, and report side effects to FDA’s MedWatch program, especially for compounded drugs: pharmacies don’t have to.358 How to report

Sources

Rules come from federal law, regulations and FDA pages; lab results from published studies and one preprint; enforcement counts from FDA’s warning-letter and recall databases. Tap a number anywhere on this page to see its source.

All sources58
  1. Composition and Labelling Accuracy of Products Sold as Retatrutide in Australia (Piatkowski et al., Drug and Alcohol Review 2026;45(6):e70231)Lab analysis · 2026(opens in a new tab)
  2. FDA warning letter to an online 'research chemicals' seller of semaglutide, tirzepatide and thymalin (issued Feb 7, 2024)Regulator · 2024(opens in a new tab)
  3. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (FDA)Regulator · 2026(opens in a new tab)
  4. Human Drug Compounding Laws (FDA)Regulator · 2024(opens in a new tab)
  5. Compounding and the FDA: Questions and Answers (FDA)Regulator · 2025(opens in a new tab)
  6. Evaluation of Research Grade Peptides Marketed Directly to Consumers Reveals Extensive Variability in Purity and Measured Abundance (Mendias & Awan, Preprints.org, 2026)Preprint · 2026(opens in a new tab)
  7. Reference Standards to Support Quality of Synthetic Peptide Therapeutics (McCarthy et al., Pharmaceutical Research 2023;40(6):1317)Review · 2023(opens in a new tab)
  8. FDA Briefing Document, Pharmacy Compounding Advisory Committee, July 23-24, 2026: BPC-157 (free base) and BPC-157 acetateRegulator · 2026(opens in a new tab)
  9. FDA warns consumers not to use counterfeit Ozempic (semaglutide) found in U.S. drug supply chain (FDA)Regulator · 2025(opens in a new tab)
  10. FDA warning letter to an online 'research use only' GLP-1 seller (issued Dec 10, 2024; one of four posted Dec 17, 2024)Regulator · 2024(opens in a new tab)
  11. FDA warning letter to an online peptide seller (gonadorelin and one other product; issued June 17, 2026)Regulator · 2026(opens in a new tab)
  12. FDA warning letter to an online peptide seller (retatrutide, semaglutide, tesamorelin and others; issued Aug 24, 2026)Regulator · 2026(opens in a new tab)
  13. Bypassing Prescribers and Pharmacists: Online Purchasing of Semaglutide and Tirzepatide "For Research Purposes" (Belcourt et al., Annals of Pharmacotherapy 2025;59(5):485-490)Review · 2025(opens in a new tab)
  14. Ability of Adults to Correctly Use Grey Market Peptide Semaglutide GLP-1 Receptor Agonists Acquired Without a Prescription (Sedensky et al., Public Health Reports 2026)Study · 2026(opens in a new tab)
  15. New Drug Application (NDA) (FDA)Regulator · 2022(opens in a new tab)
  16. Compliance Program 7346.832: Preapproval Inspections (FDA; issued 06/29/2026, implementation 08/10/2026)Government guidance · 2026(opens in a new tab)
  17. 21 CFR 210.1 - Status of current good manufacturing practice regulationsRegulation · 2026(opens in a new tab)
  18. 21 CFR 211.165 - Testing and release for distributionRegulation · 2026(opens in a new tab)
  19. 21 CFR 211.167 - Special testing requirementsRegulation · 2026(opens in a new tab)
  20. 21 U.S.C. 360 - Registration of producers of drugs or devices (risk-based inspection schedule, subsection (h))Law · 2012(opens in a new tab)
  21. Information for Outsourcing Facilities (FDA)Regulator · 2022(opens in a new tab)
  22. 21 CFR 211.84 - Testing and approval or rejection of components, drug product containers, and closuresRegulation · 2026(opens in a new tab)
  23. 21 U.S.C. 353a - Pharmacy compounding (FD&C Act section 503A)Law · 2013(opens in a new tab)
  24. 21 U.S.C. 353b - Outsourcing facilities (FD&C Act section 503B)Law · 2013(opens in a new tab)
  25. 21 CFR 314.80 - Postmarketing reporting of adverse drug experiencesRegulation · 2026(opens in a new tab)
  26. Considering Buying Medicine Online? (FDA BeSafeRx)Regulator · 2025(opens in a new tab)
  27. FDA recall database (openFDA): semaglutide and tirzepatide recalls reported January 2023 to October 2026Government · 2026(opens in a new tab)
  28. Facilities Registered as Human Drug Compounding Outsourcing Facilities Under Section 503B (FDA; as of September 30, 2026)Regulator · 2026(opens in a new tab)
  29. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (FDA; archived Oct 9, 2024)Regulator · 2024(opens in a new tab)
  30. Good Morning America / ABC News: FDA advisory committee votes to add popular peptide BPC-157 ... (Salzman S, Kekatos M; July 23, 2026)News · 2026(opens in a new tab)
  31. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize (FDA; updated 4/1/2026)Regulator · 2026(opens in a new tab)
  32. FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide from 503B Bulks List (FDA press announcement, Apr 30, 2026)Regulator · 2026(opens in a new tab)
  33. USP General Chapter <797> Pharmaceutical Compounding – Sterile Preparations (USP overview page)Standard · 2026(opens in a new tab)
  34. Multifactor Quality and Safety Analysis of Semaglutide Products Sold by Online Sellers Without a Prescription: Market Surveillance, Content Analysis, and Product Purchase Evaluation Study (Ashraf et al., J Med Internet Res 2024;26:e65440)Lab analysis · 2024(opens in a new tab)
  35. Safety and Risk Assessment of No-Prescription Online Semaglutide Purchases (Ashraf et al., JAMA Network Open 2024;7(8):e2428280)Lab analysis · 2024(opens in a new tab)
  36. Unapproved GLP-1 Drugs Retatrutide and Zenagamtide Sold Online Are No Bargain (Rubin, JAMA Medical News, Oct 9, 2026)News · 2026(opens in a new tab)
  37. Toxicity linked to unapproved peptide product labelled Retatrutide (Victoria Department of Health, health alert, 19 June 2026)Government · 2026(opens in a new tab)
  38. Impurities and Potential Immunogenicity Associated With Follow-on and Compounded Glucagon-like Peptide-1 Receptor Agonists (Kopp et al., Pharmaceutical Research 2026;43(8):2861-2886)Lab analysis · 2026(opens in a new tab)
  39. Impact of Manufacturing Process and Compounding on Properties and Quality of Follow-On GLP-1 Polypeptide Drugs (Hach et al., Pharmaceutical Research 2024;41(10):1991-2014)Lab analysis · 2024(opens in a new tab)
  40. A novel, widespread impurity in mass-compounded tirzepatide/B12 products: potential patient safety implications (Jordan et al., Expert Opinion on Drug Safety 2026;25(5):837-845)Lab analysis · 2026(opens in a new tab)
  41. TB500/TB1000 and SGF1000: A scientific approach for a better understanding of misbranded and adulterated drugs (Delcourt et al., Drug Testing and Analysis 2023;15(4):458-464)Lab analysis · 2023(opens in a new tab)
  42. The Role of Counter-Ions in Peptides - An Overview (Sikora et al., Pharmaceuticals 2020;13(12):442)Review · 2020(opens in a new tab)
  43. Purity determination of synthetic glucagon using a mass balance approach (Wang et al., Scientific Reports 2020;10:4423)Lab analysis · 2020(opens in a new tab)
  44. Facts About the Current Good Manufacturing Practice (CGMP) (FDA)Regulator · 2025(opens in a new tab)
  45. FDA warning letter to a U.S. distributor of active pharmaceutical ingredients incl. GLP-1s (issued Dec 8, 2025)Regulator · 2025(opens in a new tab)
  46. Analysis of commercially available snake antivenoms reveals high contents of endotoxins in some products (Solano et al., Toxicon: X 2024;21:100187)Lab analysis · 2024(opens in a new tab)
  47. Endotoxins and Biological Implications - Review (Ishtiaq et al., Public Health Challenges 2026;5(2):e70397)Review · 2026(opens in a new tab)
  48. Pyrogen and Endotoxins Testing: Questions and Answers, Guidance for Industry (Edition 2, March 2026) (FDA)Government guidance · 2026(opens in a new tab)
  49. Sterile Drug Products Produced by Aseptic Processing - Current Good Manufacturing Practice, Guidance for Industry (FDA, September 2004)Government guidance · 2004(opens in a new tab)
  50. Multistate Outbreak of Fungal Meningitis and Other Infections: Case Count (CDC, final counts October 30, 2015)Government · 2015(opens in a new tab)
  51. BeSafeRx: Frequently Asked Questions (FDA)Regulator · 2020(opens in a new tab)
  52. CDER Office of Compliance Annual Report 2025 (FDA)Regulator · 2026(opens in a new tab)
  53. Emerging risks of health optimisation: refractory nausea associated with peptide injections reported to contain retatrutide (Buzzi & Huber, BMJ Case Reports 2026;19(10):e276106)Study · 2026(opens in a new tab)
  54. Online-Sourced Retatrutide Complicating Impending Diabetic Ketoacidosis in a Patient With Type 1 Diabetes and Concurrent Shigella Gastroenteritis (Branine, Cureus 2026;18(8):e115260)Study · 2026(opens in a new tab)
  55. About BeSafeRx (FDA)Regulator · 2025(opens in a new tab)
  56. FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products (FDA, July 26, 2024)Regulator · 2024(opens in a new tab)
  57. FDA: Reporting Serious Problems to FDA (MedWatch; content current as of 09/26/2025)Government · 2025(opens in a new tab)
Source

Source

Open source (opens in a new tab)
Know the warning signs Explore peptides

Keep reading

Rules and the lawWhy most peptides aren’t FDA approvedWhat approval means, and why most peptides never go through it: patents, the cost of trials and the disease rule.Staying safeHow to inject peptides safelyMeasuring units on an insulin syringe, where to inject, rotating sites, keeping vials clean and getting rid of needles.Staying safeGLP-1 and peptide side effects: when to see a doctorWhich symptoms mean call 911, which mean get care today, and which to raise with your doctor.